UBS reiterates Buy on C.H. Robinson stock, sees RXO deal accretion
UBS reiterated a Buy rating on C.H. Robinson (CHRW) with a $230 price target, citing potential upside from its RXO acquisition. UBS estimates $1.15 per share accretion by 2028 in its midpoint scenario. The company's stock is down 16% over six months. Other analysts have mixed reactions to the deal, with price targets ranging from $203 to $220.
How this was made
The 30-second read
Why it matters
The acquisition is expected to be accretive to EPS and could trigger a price rally for both CHRW and RXO.
Market read
First report of a $5.8B logistics M&A with clear accretion metrics, high relevance for traders.
What to watch
Financing risk from the $4.5B bridge facility and potential regulatory review.
Background
UBS analyst reiterates Buy on CHRW with a $230 price target, citing cost synergies from the RXO acquisition.
Ticker impact
UBS reiterated a Buy on C.H. Robinson (CHRW) and detailed accretion from its $5.8B acquisition of RXO, providing new EPS impact numbers.
likely upward pressure as investors price in EPS accretion and premium valuation.
Accretion estimates and a sizable cash‑stock deal suggest material upside for CHRW shareholders.
RXO shareholders receive a $17.25 cash premium and 0.0856 CHRW shares per RXO share in the announced acquisition.
short‑term rally as market values the 29% premium.
The cash component and premium are clearly disclosed, creating immediate upside for RXO holders.
Market effects
Logistics and freight sector may see valuation lift as consolidation gains attention.
U.S. logistics stocks could experience broader buying pressure.
Mid‑cap M&A adds to overall market activity but remains sector‑focused.
Counterpoint
If synergies fall short, the deal could become dilutive, pressuring CHRW.
Key entities
- CompanyC.H. Robinson Worldwide
Logistics and freight transportation firm acquiring RXO.
- CompanyRXO
Freight brokerage being acquired by CHRW.
